Business
TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events
TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\n\n\n\n\nTNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events\n\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:\"0in\";\n}\n\n\n\n\n\n\n\n\n\n\nTNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events\n\nPR Newswire\n\nBETHESDA, Md., May 16, 2013\n\n\n\n\n\n\n\nBETHESDA, Md., May 16, 2013 /PRNewswire/ -- TNI BioTech, Inc., (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders from CEO Noreen Griffin and the company's board of directors. The letter follows:\n\n\nDear Shareholders,\n\n\nThe board of directors of TNI BioTech, Inc. is very pleased to provide an update on the progress made over the last year. This update gives the company opportunity to provide detailed reviews of several key achievements, as well as share a brief outline of the steps being taken to maximize shareholder value over the coming months.\n\n\nThe company, as of May 15, 2013, filed its first Q1 2013 financials with the Securities and Exchange Commission and OTC markets. This milestone, in conjunction with the filing of a Form 10, allows the company to become fully reporting. While waiting for approval of its Form 10, the company will file the required documents to trade on the QX OTC market, providing improved transparency to the investment community. \n\n\nThe company recently announced the hiring of Dr. Joseph Fortunak and Mr. Terry Lierman, the first of some upcoming changes that will enhance the executive team and build a world class biotech firm. In addition, the company has begun the hiring process of both a new Chief Operating Officer and President with extensive experience in biotech management. As the company prepares to up list to a national exchange, it will add to its corporate governance by forming audit and compensation committees.\n\n\nAs part of the agreement between TNI BioTech, Inc. and the University of Pennsylvania, Dr. Jill Smith, Dr. Ian S. Zagon, Dr. Patricia ...